Results 31 to 40 of about 121,777 (350)

Clinical Outcome of Intravenous Immunoglobulin in the treatment of Guillain Barre Syndrome in a Nepalese Tertiary Centre

Nepalese Medical Journal, 2019
Introduction: Intravenous Immunoglobulin is an approved therapy for Guillain Barre Syndrome. Our objective is to understand the management and outcome in Guillain Barre Syndrome patients treated with Immunoglobulin. Materials and Methods: All consecutive
Rajeev Ojha, Ragesh Karn
doaj   +1 more source

Early intravenous immunoglobulin therapy for group A β-haemolytic streptococcal meningitis with toxic shock syndrome [PDF]

BMJ Case Rep, 2021
Derick Adigbli, Valerie Rozen, Archie Darbar, Pierre Janin   +3 more
openalex   +3 more sources

Guillain-Barré syndrome: a century of progress [PDF]

, 2016
In 1916, Guillain, Barré and Strohl reported on two cases of acute flaccid paralysis with high cerebrospinal fluid protein levels and normal cell counts — novel findings that identified the disease we now know as Guillain–Barré syndrome (GBS).
A Campbell, A Chiba, A Chiba, A Pestronk, A Uncini, AA Ilyas, AD Langmuir, AJ Sumner, AK Asbury, AK Asbury, AK Asbury, AM Fitzpatrick, B Parra, B van den Berg, BH Waksman, C Brechenmacher, C Fokke, C Hafer-Macko, C Linington, CE Hafer-Macko, CL Schengrund, CP O'Leary, E Díez-Tejedor, FG van der Meché, FH Geisler, G Guillain, GM McKhann, GM O'Hanlon, H Wis´niewski, HJ Willison, Hugh J. Willison, J Kaldor, J Matias-Guiu, JA Goodfellow, JC Dodge, JG McLeod, JH Rees, JJ Plomp, JM Pearce, John A. Goodfellow, JW Albers, JW Griffin, JW Prineas, K Kaida, K Susuki, KE Astrom, KM Rhodes, KN Greenshields, LB Schonberger, LD Osler, LM Araujo, LT Kurland, M Fisher, M Kadlubowski, M Vermeulen, MK White, N Shahrizaila, N Yuki, N Yuki, N Yuki, N Yuki, NA Gregson, O Landry, PA van Doorn, PO Osterman, R McGonigal, R McGonigal, R van Koningsveld, RA Hughes, RA Hughes, RJ Greenwood, RP Kleyweg, S Draganescu, S Kusunoki, S Lafontaine, S Rinaldi, S Rinaldi, S Rinaldi, SK Halstead, SK Halstead, SK Halstead, T Lasky, T Saida, TE Feasby, TE Feasby, TW Ho, TW Ho, VM Cao-Lormeau, W Wiederholt, W Yan, WE Haymaker, Y Nagai   +91 more
core   +1 more source

Symptomatic treatment of children with anti-NMDAR encephalitis. [PDF]

, 2016
AIM: We performed the first study on the perceived benefit and adverse effects of symptomatic management in children with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis.
Brilot, F, Dale, R. C., Hong, M, Jones, H, Mohammad, Ss, Nosadini, M, Pillai, Sc, Sharpe, C   +7 more
core   +1 more source

The Cumulative Detrimental Effect of COVID-19 Pneumonia in a Patient with Myasthenic Crisis: A Case Report and Overview of the Literature

Life, 2022
Background: As the COVID-19 pandemic reached its peak, it became unavoidable that patients with other risk factors for severe pulmonary impairment (such as neuromuscular illnesses) would become afflicted.
Georgiana-Cristina Buzatu, Florin-Teodor Bobirca, Sebastian Isac, Oana Antonia Mihalache, Mihail Cotorogea-Simion, Alina Tita, Cristian Cobilinschi, Maria Daniela Tanasescu, Anca Bobirca, Gabriela Droc   +9 more
doaj   +1 more source

Intravenous immunoglobulin therapy of antiphospholipid syndrome [PDF]

Rheumatology, 2000
To review the role of intravenous immunoglobulin (IVIg) in antiphospholipid syndrome (APS).A literature search was carried out for the immunopathogenesis of APS, laboratory evidence for the beneficial effect of IVIg in APS, and the clinical use of IVIg in APS.There is both laboratory and clinical evidence for the beneficial role of IVIg in APS.
Y, Sherer, Y, Levy, Y, Shoenfeld
openaire   +2 more sources

Optimization of immunoglobulin substitution therapy by a stochastic immune response model [PDF]

, 2009
Background: The immune system is a complex adaptive system of cells and molecules that are interwoven in a highly organized communication network. Primary immune deficiencies are disorders in which essential parts of the immune system are absent or do ...
Marc Thilo Figge, Derya Unutmaz, E Mix, CA Janeway, ICM MacLennan, T Manser, M Meyer-Hermann, MT Figge, L Marodi, OC Bruton, RH Buckley, HB Gaspar, D Vetrie, S Tsukadab, JS Orange, M Stangel, M Berger, MM Eibl, J Kirmse, A Gardulf, ML Moore, H Milgrom, J Bayry, AG MacGregor, H Fujikawa, JF Van Impe, M Peleg, AS Perelson, WH Press, H Risken, MD Kazatchkine, T Tha-In, J Bayry, V Hurez, S Kaveri, P Aukrust, J Andersson, T Jungi, M Stangel, T Takai, N Prasad, MT Figge   +41 more
core   +1 more source

Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study) [PDF]

, 2013
This prospective, multicenter, single-arm, open-label Phase III study aimed to evaluate the efficacy and safety of Privigen (R) (10% liquid human intravenous immunoglobulin [IVIG], stabilized with l-proline) in patients with chronic inflammatory ...
Bauhofer, Artur, De Bleecker, Jan, Kamienowski, Jerzy, Léger, Jean-Marc, Merkies, Ingemar SJ, Mielke, Orell, Robberecht, Wim, Saarela, Mika, Shebl, Amgad, Sommer, Claudia, Stelmasiak, Zbigniew, Tackenberg, Björn, Zenker, Othmar   +12 more
core   +1 more source

Macrophage Activation Syndrome as Onset of Systemic Lupus Erythematosus: A Case Report and a Review of the Literature [PDF]

, 2015
Macrophage activation syndrome (MAS) is a potentially fatal condition. It is a rare complication of several autoimmune disorders, including systemic lupus erythematosus (SLE) and systemic juvenile idiopathic arthritis (sJIA).
Didona, Dario, Feola, Aldo, Granata, Guido, Granata, Massimo, Stifano, Giuseppina   +4 more
core   +4 more sources

A serious thrombotic event in a patient with immune thrombocytopenia requiring intravenous immunoglobulin: a case report

Journal of Medical Case Reports, 2019
Background Immune thrombocytopenia is an acquired autoimmune disease. Recently, there has been evidence of thrombotic risk in patients with immune thrombocytopenia, but the mechanism is still inconclusive.
Tarinee Rungjirajittranon, Weerapat Owattanapanich   +1 more
doaj   +1 more source